Research Paper Volume 15, Issue 12 pp 5650—5661

Development and validation of a MUC16 mutation-associated immune prognostic model for lung adenocarcinoma


Figure 2. Identification of differentially expressed genes (DEGs) in patients with lung adenocarcinoma (LUAD) with and without mucin 16 (MUC16) mutation. (A) Volcano plot and (B) heatmap of the identified DEGs. (C) Gene set enrichment analysis (GSEA) of samples with and without MUC16 mutation.